Usage: Detectnet is indicated for use with positron emission tomography (PET) to localize somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
Usage: Everolimus is indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, and for adult patients with progressive neuroendocrine tumors, renal cell carcinoma post sunitinib/sorafenib failure, renal angiomyolipoma in tuberous sclerosis, and subependymal giant cell astrocytoma in TSC.
Usage: Ga 68 DOTATOC Injection is indicated for use with PET to localize somatostatin receptor positive neuroendocrine tumors (NETs) in both adult and pediatric patients.
Usage: Iobenguane (I-123 MIBG) is indicated for diagnostic imaging of adrenomedullary disorders, neuroendocrine tumors, pheochromocytomas, paragangliomas, neuroblastomas, carcinoid tumors, and medullary thyroid carcinoma. It assists in the evaluation, localization, and confirmation of these conditions, particularly when other tests yield unclear results.
Usage: Indium In-111 pentetreotide injection is used for scintigraphic localization of primary and metastatic neuroendocrine tumors that express somatostatin receptors.
Manufacturer:Advanced Accelerator Applications USA, Inc
Usage: NETSPOT, after gallium-68 radiolabeling, is indicated for use with positron emission tomography (PET) to localize somatostatin receptor-positive neuroendocrine tumors (NETs) in both adult and pediatric patients.
Usage: Octreoscan is used for scintigraphic localization of primary and metastatic neuroendocrine tumors that express somatostatin receptors, following radiolabeling.
Usage: SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.